Search

Displaying results 831 - 840 of 4626 in total
  1. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

  2. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

  3. Drug

    Mepolizumab

    go.drugbank.com/drugs/DB06612
    ApprovedInvestigational

    The pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.

  4. Drug

    Amlodipine

    go.drugbank.com/drugs/DB00381
    ApprovedInvestigational

    Amlodipine is commonly used in the treatment of high blood pressure and angina. … Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_.

  5. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). … [A275482, L56120] Linerixibat functions by interrupting the enterohepatic circulation of these bile acids, thereby reducing their systemic concentration.[A275482]

  6. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubu...

  7. Drug

    Choline magnesium trisalicylate

    go.drugbank.com/drugs/DB01401
    Approved

    Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [A19653, A19654].

  8. Drug

    Certoparin

    go.drugbank.com/drugs/DB09261
    Approved

    Certoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.

  9. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. … A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.

  10. Pathway

    NGX267 Action Pathway

    smpdb.ca/view/SMP0126364
    Drug action

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression. Due to its mechanism of action, NGX267 may be simultaneously effec...

    Drugs: Choline · Calcium · Magnesium cation · Acetylcholine · Acetic acid · NGX267
    Enzymes: High affinity choline transporter 1